A retrospective study comparing the changes in glucose-potentiated arginine measures performed on two visits in individuals with PI-CF without diabetes and who have initiated elexacaftor/tezacaftor/ivacaftor after the baseline visit versus not treated with CFTR modulator therapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
Indications Cystic fibrosis
Focus Pharmacodynamics

Most Recent Events

29 Jul 2022 New trial record
07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight